Acceleron to Participate in Two Upcoming Healthcare Investor Conferences
Acceleron Pharma Inc. (Nasdaq:XLRN), a biopharmaceutical company dedicated to the discovery, development, and commercialization of TGF-beta superfamily therapeutics to treat serious and rare diseases, today announced that senior management will participate in two upcoming virtual healthcare investor conferences.
Conference Presentation Details:
Event: Cowen & Co. 41st Annual Health Care Conference
Date/Time: Tuesday, March 2, 2021 at 2:50 p.m. EST
Event: Barclays Global Healthcare Conference
Date/Time: Tuesday, March 9, 2021 at 10:20 a.m. EST
Live webcasts for the Cowen & Co. and Barclays conference analyst-moderated fireside chats will be accessible under “Events & Presentations” in the Investors & Media page of the Company's website at acceleronpharma.com. A replay of each webcast will be available on the Company’s website after the event.
Acceleron is a biopharmaceutical company dedicated to the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Acceleron’s leadership in the understanding of TGF-beta superfamily biology and protein engineering generates innovative compounds that engage the body's ability to regulate cellular growth and repair.
Acceleron focuses its research, development, and commercialization efforts in pulmonary and hematologic diseases. In pulmonary, Acceleron is developing sotatercept for the treatment of pulmonary arterial hypertension (PAH), having reported positive topline results of the PULSAR Phase 2 trial. The Company is currently planning multiple Phase 3 trials with the potential to support its long-term vision of establishing sotatercept as a backbone therapy for patients with PAH at all stages of the disease. Acceleron is also investigating the potential of its early-stage pulmonary candidate, ACE-1334, which it plans to advance into a Phase 1b/2 trial in systemic sclerosis-associated interstitial lung disease (SSc-ILD) this year.
In hematology, REBLOZYL (luspatercept-aamt) is the first and only erythroid maturation agent approved in the United States, Europe, and Canada for the treatment of anemia in certain blood disorders. REBLOZYL is part of a global collaboration partnership with Bristol Myers Squibb. The Companies co-promote REBLOZYL in the United States and are also developing luspatercept for the treatment of anemia in patient populations of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis.